Oral UDCA promoted weight loss and mitigated a similar cluster of metabolic disease characteristics in lean, obese, and aged mice, including lowering blood glucose, lipids, hepatic triglycerides, cholesterol, insulin resistance, and proinflammatory cytokines (98-100). This evidence concerns the gene INS and metabolic disease.